Abstract
Barrett’s esophagus (BO) is a risk factor for esophageal adenocarcinoma. However, screening for BO is difficult since it is not yet clear who should be screened and which screening method is cost-effective. Screening methods could be upper endoscopy at the time of the first screening colonoscopy, transnasal endoscopy, esophageal capsule endoscopy, or cytosponge. In order to prevent the development of BO or its neoplastic progression, there are modifiable risk factors like obesity or smoking that can be influenced. In addition, several drugs like proton pump inhibitors, aspirin, nonsteroidal anti-inflammatory drugs and statins have shown promising effects in mostly observational studies. However, data from prospective randomized trials are scarce in order to draw final conclusions.
References
1.
Weusten
B
, Bisschops
R
, Coron
E
, Dinis-Ribeiro
M
, Dumonceau
JM
, Esteban
JM
, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement
. Endoscopy
. 2017
Feb
;49
(2
):191
–8
.
[PubMed]
0013-726X2.
Sharma
P
, Dent
J
, Armstrong
D
, Bergman
JJ
, Gossner
L
, Hoshihara
Y
, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria
. Gastroenterology
. 2006
Nov
;131
(5
):1392
–9
.
[PubMed]
0016-50853.
Peters
Y
, Al-Kaabi
A
, Shaheen
NJ
, Chak
A
, Blum
A
, Souza
RF
, et al. Barrett oesophagus
. Nat Rev Dis Primers
. 2019
May
;5
(1
):35
.
[PubMed]
2056-676X4.
Pohl
H
, Welch
HG
. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence
. J Natl Cancer Inst
. 2005
Jan
;97
(2
):142
–6
.
[PubMed]
0027-88745.
Corley
DA
, Levin
TR
, Habel
LA
, Weiss
NS
, Buffler
PA
. Surveillance and survival in Barrett’s adenocarcinomas: a population-based study
. Gastroenterology
. 2002
Mar
;122
(3
):633
–40
.
[PubMed]
0016-50856.
Fountoulakis
A
, Zafirellis
KD
, Dolan
K
, Dexter
SP
, Martin
IG
, Sue-Ling
HM
. Effect of surveillance of Barrett’s oesophagus on the clinical outcome of oesophageal cancer
. Br J Surg
. 2004
Aug
;91
(8
):997
–1003
.
[PubMed]
0007-13237.
Shaheen
NJ
, Falk
GW
, Iyer
PG
, Gerson
LB
; American College of Gastroenterology
. ACG clinical guideline: diagnosis and management of Barrett’s esophagus
. Am J Gastroenterol
. 2016
Jan
;111
(1
):30
–50
.
[PubMed]
0002-92708.
Fitzgerald
RC
, di Pietro
M
, Ragunath
K
, Ang
Y
, Kang
JY
, Watson
P
, et al.; British Society of Gastroenterology
. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus
. Gut
. 2014
Jan
;63
(1
):7
–42
.
[PubMed]
0017-57499.
Bhardwaj
A
, Hollenbeak
CS
, Pooran
N
, Mathew
A
. A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett’s esophagus in patients with gastroesophageal reflux disease
. Am J Gastroenterol
. 2009
Jun
;104
(6
):1533
–9
.
[PubMed]
0002-927010.
Sami
SS
, Dunagan
KT
, Johnson
ML
, Schleck
CD
, Shah
ND
, Zinsmeister
AR
, et al. A randomized comparative effectiveness trial of novel endoscopic techniques and approaches for Barrett’s esophagus screening in the community
. Am J Gastroenterol
. 2015
Jan
;110
(1
):148
–58
.
[PubMed]
0002-927011.
Ross-Innes
CS
, Chettouh
H
, Achilleos
A
, Galeano-Dalmau
N
, Debiram-Beecham
I
, MacRae
S
, et al.; BEST2 study group
. Risk stratification of Barrett’s oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study
. Lancet Gastroenterol Hepatol
. 2017
Jan
;2
(1
):23
–31
.
[PubMed]
2468-125312.
Gupta
N
, Gaddam
S
, Wani
SB
, Bansal
A
, Rastogi
A
, Sharma
P
. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus
. Gastrointest Endosc
. 2012
Sep
;76
(3
):531
–8
.
[PubMed]
0016-510713.
Bisschops
R
, Areia
M
, Coron
E
, Dobru
D
, Kaskas
B
, Kuvaev
R
, et al. Performance measures for upper gastrointestinal endoscopy: A European Society of Gastrointestinal Endoscopy quality improvement initiative
. United European Gastroenterol J
. 2016
Oct
;4
(5
):629
–56
.
[PubMed]
2050-640614.
Bergman
JJ
, de Groof
AJ
, Pech
O
, Ragunath
K
, Armstrong
D
, Mostafavi
N
, et al.; International Working Group for Classification of Oesophagitis
. An Interactive Web-Based Educational Tool Improves Detection and Delineation of Barrett’s Esophagus-Related Neoplasia
. Gastroenterology
. 2019
Apr
;156
(5
):1299
–1308.e3
.
[PubMed]
0016-508515.
Pech
O
, Gossner
L
, Manner
H
, May
A
, Rabenstein
T
, Behrens
A
, et al. Prospective evaluation of the macroscopic types and location of early Barrett’s neoplasia in 380 lesions
. Endoscopy
. 2007
Jul
;39
(7
):588
–93
.
[PubMed]
0013-726X16.
Abela
JE
, Going
JJ
, Mackenzie
JF
, McKernan
M
, O’Mahoney
S
, Stuart
RC
. Systematic four-quadrant biopsy detects Barrett’s dysplasia in more patients than nonsystematic biopsy
. Am J Gastroenterol
. 2008
Apr
;103
(4
):850
–5
.
[PubMed]
0002-927017.
Kandiah
K
, Chedgy
FJ
, Subramaniam
S
, Longcroft-Wheaton
G
, Bassett
P
, Repici
A
, et al. International development and validation of a classification system for the identification of Barrett’s neoplasia using acetic acid chromoendoscopy: the Portsmouth acetic acid classification (PREDICT)
. Gut
. 2018
Dec
;67
(12
):2085
–91
.
[PubMed]
0017-574918.
Sharma
P
, Bergman
JJ
, Goda
K
, Kato
M
, Messmann
H
, Alsop
BR
, et al. Development and Validation of a Classification System to Identify High-Grade Dysplasia and Esophageal Adenocarcinoma in Barrett’s Esophagus Using Narrow-Band Imaging
. Gastroenterology
. 2016
Mar
;150
(3
):591
–8
.
[PubMed]
0016-508519.
Ebigbo
A
, Messmann
H
, Roemele
C
. Screening upper gastrointestinal endoscopy
. Visc Med
. 2019
;•••
: 2297-472520.
Singh
S
, Sharma
AN
, Murad
MH
, Buttar
NS
, El-Serag
HB
, Katzka
DA
, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis
. Clin Gastroenterol Hepatol
. 2013
Nov
;11
(11
):1399
–1412.e7
.
[PubMed]
1542-356521.
Kubo
A
, Cook
MB
, Shaheen
NJ
, Vaughan
TL
, Whiteman
DC
, Murray
L
, et al. Sex-specific associations between body mass index, waist circumference and the risk of Barrett’s oesophagus: a pooled analysis from the international BEACON consortium
. Gut
. 2013
Dec
;62
(12
):1684
–91
.
[PubMed]
0017-574922.
Krishnamoorthi
R
, Singh
S
, Ragunathan
K
, Visrodia
K
, Wang
KK
, Katzka
DA
, et al. Factors associated with progression of Barrett’s esophagus: a systematic review and meta- analysis
. Clin Gastroenterol Hepatol
. 2018
Jul
;16
(7
):1046
–1055.e8
.
[PubMed]
1542-356523.
Chandar
AK
, Devanna
S
, Lu
C
, Singh
S
, Greer
K
, Chak
A
, et al. Association of serum levels of adipokines and insulin with risk of Barrett’s esophagus: a systematic review and meta- analysis
. Clin Gastroenterol Hepatol
. 2015
Dec
;13
(13
):2241
–55.e1
.
[PubMed]
1542-356524.
Ayazi
S
, Hagen
JA
, Chan
LS
, DeMeester
SR
, Lin
MW
, Ayazi
A
, et al. Obesity and gastroesophageal reflux: quantifying the association between body mass index, esophageal acid exposure, and lower esophageal sphincter status in a large series of patients with reflux symptoms
. J Gastrointest Surg
. 2009
Aug
;13
(8
):1440
–7
.
[PubMed]
1091-255X25.
Cook
MB
, Shaheen
NJ
, Anderson
LA
, Giffen
C
, Chow
WH
, Vaughan
TL
, et al. Cigarette smoking increases risk of Barrett’s esophagus: an analysis of the Barrett’s and Esophageal Adenocarcinoma Consortium
. Gastroenterology
. 2012
Apr
;142
(4
):744
–53
.
[PubMed]
0016-508526.
Andrici
J
, Cox
MR
, Eslick
GD
. Cigarette smoking and the risk of Barrett’s esophagus: a systematic review and meta-analysis
. J Gastroenterol Hepatol
. 2013
Aug
;28
(8
):1258
–73
.
[PubMed]
0815-931927.
Balasubramanian
G
, Gupta
N
, Giacchino
M
, Singh
M
, Kanakadandi
V
, Gaddam
S
, et al. Cigarette smoking is a modifiable risk factor for Barrett’s oesophagus
. United European Gastroenterol J
. 2013
Dec
;1
(6
):430
–7
.
[PubMed]
2050-640628.
Koop
H
, Schepp
W
, Müller-Lissner
S
, Madisch
A
, Micklefield
G
, Messmann
H
, et al. [Consensus conference of the DGVS on gastroesophageal reflux]
. Z Gastroenterol
. 2005
Feb
;43
(2
):163
–4
.
[PubMed]
0044-277129.
Abu-Sneineh
A
, Tam
W
, Schoeman
M
, Fraser
R
, Ruszkiewicz
AR
, Smith
E
, et al. The effects of high-dose esomeprazole on gastric and oesophageal acid exposure and molecular markers in Barrett’s oesophagus
. Aliment Pharmacol Ther
. 2010
Oct
;32
(8
):1023
–30
.
[PubMed]
0269-281330.
Singh
S
, Garg
SK
, Singh
PP
, Iyer
PG
, El-Serag
HB
. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis
. Gut
. 2014
Aug
;63
(8
):1229
–37
.
[PubMed]
0017-574931.
Jankowski
JA
, de Caestecker
J
, Love
SB
, Reilly
G
, Watson
P
, Sanders
S
, et al.; AspECT Trial Team
. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial
. Lancet
. 2018
Aug
;392
(10145
):400
–8
.
[PubMed]
0140-673632.
Liao
LM
, Vaughan
TL
, Corley
DA
, Cook
MB
, Casson
AG
, Kamangar
F
, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis
. Gastroenterology
. 2012
Mar
;142
(3
):442
–452.e5
.
[PubMed]
0016-508533.
Zhang
S
, Zhang
XQ
, Ding
XW
, Yang
RK
, Huang
SL
, Kastelein
F
, et al. Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a meta-analysis
. Br J Cancer
. 2014
Apr
;110
(9
):2378
–88
.
[PubMed]
0007-092034.
Ogunwobi
OO
, Beales
IL
. Statins inhibit proliferation and induce apoptosis in Barrett’s esophageal adenocarcinoma cells
. Am J Gastroenterol
. 2008
Apr
;103
(4
):825
–37
.
[PubMed]
0002-927035.
Nguyen
T
, Khalaf
N
, Ramsey
D
, El-Serag
HB
. Statin use is associated with a decreased risk of Barrett’s esophagus
. Gastroenterology
. 2014
Aug
;147
(2
):314
–23
.
[PubMed]
0016-508536.
Nguyen
T
, Duan
Z
, Naik
AD
, Kramer
JR
, El-Serag
HB
. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett’s esophagus: a nested case-control study
. Gastroenterology
. 2015
Nov
;149
(6
):1392
–8
.
[PubMed]
0016-5085© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
